Federation des caisses Desjardins du Quebec’s Palvella Therapeutics PVLA Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18	Closed	-$1.88K	–	3110
2025 Q4	$1.88K	Buy	+18	New	+$1.54K	﹤0.01%	2604
2021 Q2	–	Sell	-1,129	Closed	-$232K	–	2587
2021 Q1	$232K	Sell	1,129 -813	-42%	-$178K	﹤0.01%	1073
2020 Q4	$388K	Sell	1,942 -307	-14%	-$63.8K	﹤0.01%	852
2020 Q3	$373K	Hold	2,249	–	–	0.01%	725
2020 Q2	$559K	Hold	2,249	–	–	0.01%	631
2020 Q1	$415K	Sell	2,249 -237	-10%	-$59.7K	0.01%	680
2019 Q4	$719K	Hold	2,486	–	–	0.01%	708
2019 Q3	$679K	Sell	2,486 -89	-3%	-$34.5K	0.01%	709
2019 Q2	$966K	Hold	2,575	–	–	0.01%	651
2019 Q1	$690K	Hold	2,575	–	–	0.01%	675
2018 Q4	$549K	Buy	2,575 +635	+33%	+$197K	0.01%	707
2018 Q3	$870K	Hold	1,940	–	–	0.01%	644
2018 Q2	$788K	Buy	1,940 +1,396	+257%	+$664K	0.01%	675
2018 Q1	$297K	Buy	+544	New	+$337K	﹤0.01%	888

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's PVLA Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 18 shares — an estimated $1.88K sold.

Federation des caisses Desjardins du Quebec first reported a position in PVLA in Q1 2018 and held it in 14 quarters. The position peaked at $966K in Q2 2019. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Federation des caisses Desjardins du Quebec reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 18 Palvella Therapeutics shares in Q1 2026, an estimated $1.88K.
Federation des caisses Desjardins du Quebec first reported a position in Palvella Therapeutics in Q1 2018 and held it in 14 quarters.
Federation des caisses Desjardins du Quebec's Palvella Therapeutics position peaked at $966K in Q2 2019.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.